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Understanding cell-type-specific epigenetic codes on a global level is a major challenge after the sequencing of the human genome has been
completed. Here we applied methyl-CpG immunoprecipitation (MCIp) to obtain comparative methylation profiles of coding and noncoding genes
in three human tissues, testis, brain, and monocytes. Forty-four mainly testis-specific promoters were independently validated using bisulfite
sequencing or single-gene MCIp, confirming the results obtained by the MCIp microarray approach. We demonstrate the previously unknown
somatic hypermethylation at many CpG-rich, testis-specific gene promoters, in particular in ampliconic areas of the Y chromosome. We also
identify a number of miRNA genes showing tissue-specific methylation patterns. The comparison of the obtained tissue methylation profiles with
corresponding gene expression data indicates a significant association between tissue-specific promoter methylation and gene expression, not only
in CpG-rich promoters. In summary, our study highlights the exceptional epigenetic status of germ-line cells in testis and provides a global insight
into tissue-specific DNA methylation patterns.
© 2007 Elsevier Inc. All rights reserved.Keywords: DNA methylation; Epigenetics; Gene regulation; Methylation profilingThe epigenetic code comprises a second layer of information
on top of the genetic code. Whereas the latter provides the
framework for RNA and protein structure, the epigenetic code
controls the packaging of DNA and ultimately regulates gene
expression [1,2]. In mammals, methylation of cytosine residues
in CpG dinucleotides is a frequent epigenetic mark that is
required for normal embryonic development. DNA methylation
plays important roles in gene regulation, e.g., in X-chromosome
inactivation, imprinting, or silencing of retrotransposons, and is
mostly associated with gene repression [1,2]. Global methyla-
tion patterns are established at the time of implantation and
usually only a small portion of the genome remains unmodified
[3]. Regions that are generally free of methylated CpG
dinucleotides include the so-called CpG islands that are
believed to be protected from methylation through cis-acting
elements [4]. In contrast, CpG-depleted regions that are in-☆ Sequence data from this article have been deposited with the GEO Data
Library under Series Entry GSE5548.
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doi:10.1016/j.ygeno.2007.04.011volved in gene regulation often show a dynamic, tissue-specific
pattern of CpG methylation [1,2].
The extent of tissue-specific hyper- or hypomethylation
throughout the genome is largely unknown, and its role in gene
regulation and development has been controversially discussed
[5,6]. The key to a better understanding of DNA methylation
will be a more global picture of its tissue-specific and
interindividual variations. However, few methods can be
applied to detect DNA methylation genome-wide. Most
currently used techniques to map global methylation differences
involve the restriction of DNA with methylation-sensitive
enzymes [7,8], thereby limiting these approaches to a relatively
small number of unique restriction sites. Some improvement of
those strategies may be offered by combining traditional
methylation-sensitive enzymes with McrBC, an enzyme com-
plex from Escherichia coli that degrades methylated DNA
between two methylated half-sites of the form (G/A)mC
separated by 40–3000 bp, as demonstrated in some recent
studies [9,10]. The most accurate methylation profiling
techniques are based on bisulfite treatment of DNA. However,
those approaches are expensive, laborious, and not readily
applicable on a genome-wide level. Nevertheless, the Human
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using bisulfite technology, and the analysis of about 2500
amplicons across three chromosomes in 12 different tissues has
been published recently [11]. Although this approach signifi-
cantly advances our understanding of human epigenetics, it is
clear that cheaper and faster high-throughput profiling plat-
forms are needed to expedite the decoding of the human
epigenome.
The separation of relatively small pieces of genomic DNA on
the basis of their methylation density might represent an
interesting technical alternative to current approaches. Here, we
describe an adaptation of the methyl-CpG immunoprecipitation
technique [12] for the detection of hypomethylated DNA
fragments. We present global comparative methylation patterns
for gene promoters in three human tissues and identify many
promoters showing tissue-specific hypermethylation in brain,
testis, or monocytes. In combination with whole-genome
microarrays, our approach is suited to detecting differences in
tissue- or cell-type-specific DNA methylation patterns in
nonrepetitive regions throughout the genome.
Results and discussion
Genome-wide detection of tissue-specific hypomethylation by
methyl-CpG immunoprecipitation
Methyl-CpG immunoprecipitation (MCIp) is based on a
recombinant MBD2–Fc fusion protein that was originally
designed by our lab to detect globally disease-related hype-
rmethylation in CpG islands [12,13]. In contrast to another
recently developed immunoprecipitation approach using 5-
methyl-specific antibodies (called MeDIP or mDIP) that
specifically enriches for methylated fragments [14,15], MCIp
can divide the bulk of genomic DNA fragments into separate
fractions of increasing methylation density [12]. Therefore, it
should allow the simultaneous, quantitative analysis of the
whole range of DNA-methylation density, including both
hyper- and hypomethylated DNA.
It is currently believed that tissue-specific variations in
DNA methylation largely occur in CpG-depleted promoters,
whereas most CpG island promoters remain unmethylated in
all tissues [2]. We hypothesized that most tissue-specific
methylation differences may therefore be detected in the
nonbinding fraction of a methyl-CpG immunoprecipitation
that contains DNA fragments with no or only very few
methylated CpG dinucleotides. We modified the previously
described procedure to separate unmethylated DNA fragments
rapidly as follows. In contrast to the original approach,
genomic DNA was fragmented to a mean of 400–500 bp by
ultrasonication rather than restriction digestion to avoid bias.
To allow the direct labeling of DNA fragments for subsequent
microarray analysis without prior amplification, we used
4 μg, instead of 300 ng, of genomic DNA fragments that
were processed in large spin columns, and we processed and
analyzed the unbound DNA fraction that was obtained
immediately after the binding reaction. The salt concentration
of the binding buffer was adjusted to allow the flowthroughof fragments methylated at few sites (one or two mCpG’s).
The final strategy for purification and subsequent detection of
the fractionated material is summarized in Fig. 1, which also
shows a typical MCIp fractionation of a maternally imprinted
gene (SNRPN). As demonstrated in this example, the
modified MCIp approach efficiently separates the methylated
and the unmethylated alleles in somatic tissues, whereas the
majority of this locus, as expected, appears unmethylated in
testis.
To demonstrate the feasibility of this method to detect tissue-
specific differences in methylation levels on a global scale, we
separated unmethylated DNA fragments from three different
tissues (testis, brain, monocytes) by MCIp. The purified DNA
fragments were labeled directly with fluorescent dyes. Testis
DNA fragments were cohybridized with either monocyte or
brain DNA fragments onto human promoter arrays containing
44,000 oligonucleotide probes (45- to 60-mer) corresponding to
nonrepetitive sequences and representing approximately 17,000
annotated genes and approximately 20,000 promoters. To limit
interindividual differences and to increase the significance of
our analysis, we performed two hybridizations per comparison
using two independent testis samples (biological replicates).
Fig. 2 shows representative scatter plots of MCIp microarray
analyses. On a global scale, testis DNA fragments reproducibly
appeared to be less methylated than brain or monocyte DNA,
and brain was usually less different from testis than monocytes.
We assumed that DNA methylation in proximal promoter
regions (−600 to +200 relative to the transcription start site)
would be most influential in terms of gene regulation and
focused our analysis on oligonucleotide probes located in
proximal promoter regions that were enriched significantly
(pb0.01 for processed signals) and more than 2.4-fold different
between samples to ensure a major difference in the degree of
methylation. At a mean fragment size of 400–500 bp, a single
oligonucleotide probe should detect methylation events within a
radius of at least 350 bp. Since we allowed the flowthrough of
fragments methylated at one or two mCpG’s during the MCIp
binding reaction, a given DNA fragment should contain at least
four or five CpG residues within the above radius, to allow the
reproducible separation of unmethylated and methylated
fragments. Therefore, we calculated the number of CpG
residues in a region 350 bp upstream and downstream of each
probe (CpG index) and restricted our analysis to probes with a
CpG index above 4, thereby excluding less than 10% of all
probes in proximal promoter regions and 4% of all proximal
promoters. A proximal gene promoter was considered com-
paratively less methylated (hypomethylated) if at least one
promoter probe was consistently different in both hybridization
experiments using the above criteria. A promoter was grouped
as hypomethylated in testis if it was less methylated compared
to both somatic tissues. Promoters were grouped as hypo-
methylated in brain (monocytes) if they appeared less
methylated in the brain (monocyte)/testis comparisons but not
significantly different in the monocyte (brain)/testis hybridiza-
tions. In total, we identified 283 gene promoters that were
specifically hypomethylated in testis. In brain and monocytes,
123 and 190 gene promoters, respectively, were specifically
Fig. 2. Global profiling of tissue DNA methylation using human promoter microarrays. MvA plots (log2 signal ratio versus log2 processed signal testis) are shown for
representative hybridization experiments of human testis versus (A) monocytes or (B) brain. Black spots represent probes that were not significantly changed
(pN0.01), blue spots were significantly enriched (ratio b2.4), and red spots were significantly enriched (pb0.01) and N2.4-fold different.
Fig. 1. MCIp-on-Chip approach to detect promoter regions with tissue-specific hypomethylation. Genomic DNA of tissue or purified cell populations is fragmented to
a mean size of 400–500 bp using ultrasonication (Step 1). The material is bound to MBD–Fc Sepharose beads at 350 mM NaCl for 3 h (Step 2) and fractionated using
wash/elution buffers containing increasing concentrations of NaCl (400–1000 mM, Step 3). For single-gene analysis, the amount of a single gene fragment may be
quantified by real-time PCR in each fraction (Step 4a). The data of an exemplary analysis of the SNRPN promoter are graphically shown for the five tissue samples
brain, liver, monocytes, testis sample 1, and testis sample 2 as a heat map. The percentage of amplified material in a given fraction is represented by gray coloring.
Since the SNRPN promoter is subject to maternal imprinting, approximately half of the amplified material in somatic tissues is present in the 350 mM fraction
(unmethylated). The second half elutes mainly above 570 mMNaCl, representing the methylated alleles. As expected, germ-line cells in testis lack the maternal imprint
and approximately 75% of the SNRPN fragments are found in the unmethylated fraction. As an alternative to single-gene analysis, individual fractions (here the
unmethylated 350 mM NaCl fraction) of two tissues may be used for dual-color microarray analysis (Step 4b).
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596 identified promoters is given in Supplementary Table 1.
Structure of tissue-specifically hypomethylated promoters
Assuming that a single oligonucleotide probe should detect
methylation events within a radius of at least 350 bp (as
detailed above) we expected that methylated CpG islands or
Alu repeats may affect a probe signal within a 250-to 350-
bp distance. We therefore determined the presence of classical
CpG islands [16] or Alu repeats [17] in the vicinity of
individual probes at radii of 250, 350, and 850 bp around
each probe. Notably, strikingly more hypomethylated promo-
ters were associated with CpG islands in testis than in either
somatic tissue (see Fig. 3A) at all distances (pb0.0001). This
observation is in line with the previously postulated general
absence of tissue-specific variation in somatic CpG island
methylation. The marked association of testis-specific hypo-
methylation with CpG island promoters extends earlier studies
reporting the somatic methylation of individual, so-called
cancer-testis antigens, which are generally controlled by CpG-
rich promoters [18,19].Fig. 3. Association of hypomethylated promoters with CpG islands and Alu
repeats. Graphical presentations of a probe (50 bp), detected fragments (mean of
450 bp), and distances used to determine overlaps with (A) CpG islands and (B)
Alu repeats. The presence of CpG islands or Alu repeats in the vicinity of
proximal promoter probes (±250, 350, or 850 bp) was calculated for all
individual promoter regions with a CpG index above 4 (All; 19,145 promoters in
total) or within each hypomethylated group (testis, brain, and monocytes with
283, 123, and 190 promoters, respectively). The percentage of association of
hypomethylated probes within a given radius with either (A) CpG islands or (B)
Alu repeats is shown relative to all promoters in a group.Previous studies indicated that Alu repeats in testis may be
less methylated in general than those in somatic cells;
however, little information on the positions of hypomethy-
lated Alu’s is available [20]. Oligonucleotide probes on the
microarray do not correspond directly to repetitive sequences;
however, they may be located next to repeats and detect their
methylation status as detailed above. When comparing the
percentage of hypomethylated promoters that are associated
with Alu repeats, we noticed a significantly higher incidence
of Alu repeats in the vicinity of promoter sequences that were
hypomethylated in testis compared to the other two tissues.
The difference was obvious at all distances but was most
significant at 250 bp around individual hypomethylated
probes (pb0.0001). This represents further indication of a
role for Alu repeats in testis-specific gene regulation.
Genes with tissue-specifically hypomethylated promoters
were generally found on all chromosomes (data not shown).
An accumulation of testis-specific hypomethylation that has
not been observed previously was detected on the Y chromo-
some, on which several of the annotated genes appeared hypo-
methylated compared to both somatic tissues (see Fig. 4A
and below) and, as described earlier, on the X chromosome
[21].
Validation of MCIp microarray results
To validate the MCIp microarray data, we initially focused
on the Y chromosome and analyzed all CpG-rich promoters of
testis-specific genes in ampliconic areas [22] and a number of
additional, randomly chosen genes of the Y chromosome by
MCIp and subsequent real-time PCR. As shown in Fig. 4B,
single-gene MCIp data corresponded well with the micro-
array data confirming the somatic hypermethylation of most
testis-specific genes, especially in ampliconic areas of the Y
chromosome.
A similar degree of correlation was observed with tissue-
specifically hypomethylated gene promoters on other chromo-
somes. The extended analysis of 44 gene promoters using MCIp
and/or bisulfite sequencing is summarized in Table 1 (heat maps
and additional bisulfite sequencing data are available as
Supplementary Figs. 1 and 2, respectively). A number of pre-
vious studies already noted the testis-specific hypomethylation
of selected genes. Our analysis confirmed the testis-specific
methylation status published for DDX4 [7] and ACTL7B [23],
as well as TAF7L and LUZP4 [21]. In our microarray analysis,
MAGEA1 and TKTL1, which had been analyzed previously by
bisulfite sequencing [18,21], were detected as hypomethylated
in only one of the two testis samples tested. The latter was also
true for two of three genes (TYROBP and MIRN363) that tested
as false negatives on the microarray. The causes of discrepant
results in some cases are unknown. Sources of potential errors
include the possibly inefficient or nonspecific detection of
individual probes on the microarray, normalization artifacts
during data processing, or experimental variation, e.g., through
interexperimental differences in ultrasonication efficiency. In
total, 35 of 40 validated gene promoters demonstrated the same
methylation profile in global and single-gene analysis. Taken
Fig. 4. Tissue-specific methylation profiles of the human Y chromosome. (A) Schematic representation of microarray results from one of two hybridizations for the
human Y chromosome. Log2 signal ratios for each probe are represented relative to their absolute chromosomal position (based on NCBI build 35). Black spots
represent probes that were not significantly changed (pN0.01), blue spots were significantly enriched but less than 2.4-fold different, and red spots were significantly
enriched (pb0.01) and N2.4-fold different. The positions of genes shown in (B) are indicated. (B) Graphical presentation of single-gene MCIp real-time PCR data for
several tested Y-chromosome genes. Gene symbols, copy numbers, and representative chromosomal localizations of the amplified product (based on NCBI build 35 of
the human genome sequence) are given above the heat maps, which represent the percentages of amplified material in a given NaCl fraction by gray coloring for DNA
samples of brain (B), liver (L), monocytes (M), testis sample 1 (T1), and testis sample 2 (T2) as described for Fig. 1.
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reproducibility.
It is noteworthy that tissue-specific variations in promoter
methylation were also detected in several noncoding micro-
RNAs as exemplified by MIRN127, 142, 338, and 363 (see
Table 1 and Supplementary Fig. 1). A recent publication des-
cribed the testis-specific demethylation of MIRN127 and its
activation in somatic tissues by chromatin-modifying drugs
[24], confirming our MCIp result.
Evidence for promoter-specific mechanisms establishing the
hypermethylation of some CpG islands in somatic tissues
In addition to the large number of testis-specific gene
promoters that demonstrated hypermethylation in somatic
tissues, we also noted a large group of testis-specific genes
that did not exhibit a differential methylation status in any of
the studied tissues, suggesting that only a subgroup of testis-
specific genes is affected by somatic hypermethylation. For
example, AKAP3, DMRT1, TEKT3, or TTTY14 gene pro-
moters were generally unmethylated in all tissues examined
(see Fig. 4B and Supplementary Fig. 1). We also noted that
copies of Y-linked genes like DAZL (chromosome 3) or VCX
(chromosome X) that share almost identical promoter regions
with their gene homologues on chromosome Y (DAZ and
VCY, respectively) also show somatic hypermethylation,
whereas homologous genes that are regulated by differentpromoter sequences (data not shown), like RBMX (chromo-
some X) or TSPYL5 (chromosome 8), show a different
methylation profile compared to their Y-chromosome homo-
logues RBMY1A1 and TSPY1 (see Fig. 4B and Supplementary
Fig. 1). The SYBL1 genes on both X and Y chromosomes
appear to represent an exception in having almost identical
promoters but being solely methylated on the Y chromosome
[25]. Based on the methylation characteristics of SYBL1, the
existence of Y-chromosome inactivation resembling the well-
known X-chromosome inactivation in females was previously
proposed [25]. However, according to the methylation pattern
of all other Y-chromosome genes that were analyzed in our
study, this kind of phenomenon appears to be restricted to the
short pseudo-autosomal region on Yq, which is flanked by a
large heterochromatic region.
The above observations strongly suggest the presence of
sequence-specific regulatory mechanisms controlling either
the specific demethylation of some promoters in testis or
germ-line cells or their global methylation in somatic tissues.
Common cis-acting sequences responsible for this phenom-
enon are unknown so far and we failed to associate specific
DNA motifs with either group of promoters. The methylation
of CpG islands in lymphocytes was recently shown to
correlate with DNA sequence, repeats, and predicted DNA
structure using bioinformatics scoring and prediction methods,
suggesting that multiple factors may predispose CpG islands
for DNA methylation [26]. Recent studies have shown that
Table 1
Profiles of promoter hypomethylation and mRNA expression for selected genes in brain, testis, and monocytes
Gene symbol CGI promoter a Chromosome MCIp array MCIp PCRb Bisulfite c mRNA expression d
BACH (ACOT7) No 1 Brain e Brain e Brain e Brain
CORT No 1 Brain Brain — Ubiquitous
DAZL Yes 3 Not diff. f Testis — Testis
MORC1 Yes 3 Testis Testis — Testis
TSPYL5 Yes 8 Testis, brain Testis, brain — Testis, brain, blood
DMRT1 Yes 9 Not diff. Not diff. — Testis
TLR4 No 9 Mono Mono Mono Blood
LMO2 No 11 Mono Mono — Blood, endothelium
CLPB Yes 11 Testis, brain Testis, brain — Testis
SPTBN2 No 11 Brain Brain — Testis, brain, other
AKAP3 No 12 Not diff. Not diff. — Testis
FGF6 Yes 12 Testis Testis — Testis, muscle
H1FNT No 12 Testis Testis — Testis
MGP No 12 Mono Not diff. — Ubiquitous (not blood)
MIRN127 Yes 14 Testis Testis — Testis
APBA2 No 15 Brain Brain — Brain, blood
SNRPN Yes 15 Testis Testis — Ubiquitous (imprinted)
PRM1 No 16 Not diff. Not diff. — Testis
MIRN142 No 17 Mono Mono — n.a.
MIRN338 No 17 Brain Brain — n.a.
TEKT3 Yes 17 Not diff. Not diff. — Testis
AURKC (up) g Yes 19 Testis Testis — Testis
TYROBP No 19 Not diff. (mono) h Mono — Blood
ZSCAN5 Yes 19 Testis — Testis Testis
PRAME Yes 22 Testis Testis — Testis
DCX No X Mono Not diff. — Fetal brain
MAGEB10 No X Testis Testis Testis n.a.
MIRN363 No X Not diff. (brain) Brain — n.a.
RBMX Yes X Not diff. Not diff. — Ubiquitous
TAF7L No X Testis Testis — Testis
VCX No X n.a. Testis — Testis
DAZ1 Yes Y n.a. Testis — Testis
DDX3Y (up) g No Y Testis Testis — Testis, blood
EIF1AY No Y Not diff. Not diff. — Blood
NLGN4Y Yes Y Not diff. Not diff. — Ubiquitous
PRY No Y Not diff. Not diff. — Testis
RBMY1A1 Yes Y Testis Testis — Testis
SYBL1 Yes Y n.a. Testis — Testis
TGIF2LY No Y Testis Testis Testis Testis
TMSB4Y Yes Y Not diff. Not diff. — Ubiquitous
TSPY1 Yes Y Testis Testis — Testis
TTTY14 Yes Y n.a. Not diff. — Testis
UTY No Y Testis, brain Testis, brain — Ubiquitous
VCY No Y Testis Testis — Testis
a The presence or absence of a CpG island in the 5′-proximal promoter region (CGI promoter) was determined using the RepeatMasker function in the UCSC
Genome browser (http://genome.ucsc.edu/).
b Single-gene MCIp data are shown in Fig. 4 and Supplementary Fig. 1. Data obtained with the liver DNA sample were not included.
c Bisulfite data are shown in Supplementary Fig. 2.
d Expression data indicate the primary source of expression according to the reference databases SymAtlas and RefEXA (see Materials and methods).
e The indicated tissue(s), e.g., brain, was found to be less methylated (hypomethylated) compared to the two other tissues used in the microarray study, e.g., testis and
monocytes. Data obtained with the liver DNA sample in single gene MCIp were not included.
f Abbreviations used: not diff., not significantly different; n.a., not available.
g Single-gene MCIp PCR primers for AURKC and DDX3Y were located N600 bp upstream (up) of the putative transcription start site in a region that was
differentially methylated as indicated. The proximal region was not significantly different in both cases.
h The promoters of TYROBP and MIRN363 were significantly different in only one of two hybridizations; however, they showed the same trend in each case (the
respective tissue is given in parentheses).
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BORIS/CTCFL [27] can initiate the demethylation of the
cancer-testis antigens MAGEA1 [28] and NY-ESO-1 [29] in
normal somatic cells, suggesting that this transcription factor
may be involved in the testis-specific demethylation of atleast some of the somatically methylated promoters. Another
recent report indicates that E2F6 may be essential for the
long-term somatic silencing of certain male-germ-cell-specific
genes [30]. Taken together, the above observations favor a
model in which specific cis-acting sequences control promoter
320 E. Schilling, M. Rehli / Genomics 90 (2007) 314–323methylation at the level of somatic hypermethylation rather
than testis-specific demethylation.
Relationship between DNA methylation and gene expression
In contrast to CpG island promoters, the effect of DNA
methylation on CpG-depleted promoters has been controversial.
A number of recent studies did not support a major role for
DNA methylation in tissue-specific gene regulation [5,6].
However, so far, systematic comparisons on a genome-wide
level have not been performed. To correlate our CpG methy-Fig. 5. Comparison of methylation and expression profiles. (A–C) Distribution of exp
or (C) monocytes. Only genes with traceable expression profiles were included. (D)
group.lation data and gene expression patterns, we extracted RNA
expression data from publicly available reference databases
(Symatlas, RefEXA) for all corresponding differentially
methylated fragments. The distribution of expression patterns
for tissue-specifically hypomethylated fragments is summar-
ized in Figs. 5A–5C. The largest group of testis-hypomethy-
lated genes (38%) was specifically expressed in testis.
Expression of genes that were hypomethylated in monocytes
or brain was also often specific for the respective gene (19 or
20%, respectively). Interestingly, most genes in the monocyte-
hypomethylated group were transcribed specifically in theression patterns for genes with hypomethylated promoters in (A) testis, (B) brain,
Distribution of testis-, brain-, or monocyte-specific genes in each demethylated
321E. Schilling, M. Rehli / Genomics 90 (2007) 314–323hemopoietic system, which may suggest an association of
DNA methylation patterns with the origin of a cell type
(hemopoietic) rather than the specialized cell type itself
(monocyte). The coexistence of DNA methylation and
transcription in a certain tissue was also detected. Transcription
may indeed proceed in the presence of DNA methylation at
those sites. However, there are a number of possibilities that
may also explain these observations, including alternative
promoter usage or simply false-positive microarray signals. A
larger number of microarray experiments may be necessary for
an in-depth analysis and further analyses of individual genes
will be required to clarify these issues.
Tissues are generally composed of different, specialized
cell types, which likely results in mixed gene expression and
methylation patterns, as exemplified by bisulfite sequences
presented in Supplementary Fig. 2. It is therefore difficult, if
not impossible, to correlate tissue methylation or expression
patterns for all genes, because both signatures may be deter-
mined by independent cell populations within the tissue. In the
case of highly tissue-specific genes a significant correlation
between expression and methylation pattern may exist,
although some studies did not support this kind of relationship
[5,6]. When we determined the number of genes that showed a
restricted expression pattern in testis, monocytes, or brain
within each group of hypomethylated genes, the number of
genes expressed in a certain tissue was significantly enriched
(pb0.0001) in the hypomethylated group of the same tissue.
This observation suggests that tissue-specific DNA hypo-
methylation correlates significantly with tissue-specific trans-
cription (see Fig. 5D).
It is clear that the presented pilot study provides only an
initial and limited view of the human methylation landscape.
Interindividual methylation variability, which may be key to
understanding the role of methylation in gene regulation, has
not been addressed in our study and, due to the fact that
tissues are composed of different cell types, only differences
in dominant cell types are likely being detected in our ex-
periments. Further studies using purified cell populations and
including matched methylation and expression profiling will
be necessary to understand completely the relationship bet-
ween DNA methylation and gene expression.
Toward decoding the human epigenome
We present a novel technical approach that allows the
detection of hypomethylated DNA fragments on a global level.
Our approach is specifically designed to enable the quantitative
detection of cell type-specific differences in DNA hypomethy-
lation with a reasonable resolution and should allow routine
methylation profiling comparable to microarray-based expres-
sion studies. Although the presented study focused on promoter
regions, the same strategy can also be used to screen methy-
lation patterns across all nonrepetitive regions of the genome,
depending on the availability of microarrays. In combination
with existing technologies, the described MCIp microarray
approach will likely make a significant contribution toward
decoding the human epigenome.Materials and methods
Reagents
All chemical reagents were purchased from Sigma–Aldrich (Taufkirchen,
Germany) unless otherwise noted. Standard oligonucleotides were synthesized
by Operon Biotechnologies GmbH (Cologne, Germany). HPLC-purified
oligonucleotides were obtained from Metabion (Planegg–Martinsried, Ger-
many). DNA sequencing was done by Geneart (Regensburg, Germany).
DNA preparation and fragmentation
Human monocytes from male donors were isolated as previously described
[31]. Genomic DNA (gDNA) from monocytes was prepared using the Blood
and Cell Culture DNA Midi Kit from Qiagen (Hilden, Germany). Male gDNA
from brain, liver, and two testis samples was purchased from BioChain Institute
(Hayward, CA, USA). For MCIp, gDNAwas fragmented as follows: To reduce
viscosity, gDNAwas initially sheared using a 0.4×19-mm needle attached to a
2-ml syringe (BD, Drogheda, Ireland) before quantification using either
PicoGreen dsDNA quantitation reagent (Molecular Probes, Eugene, OR,
USA) or the NanoDrop ND 1000 spectrophotometer (Peqlab, Erlangen,
Germany). Ultrasonication to a mean fragment size of 400–500 bp was carried
out with the Branson Sonifier 250 (Danbury, CT, USA) using the following
settings: duty cycle 30%, output 3, sonication time 1 min, and 5 μg DNA in
500 μl TE buffer. Fragment range was controlled using agarose gel
electrophoresis.
Methyl-CpG immunoprecipitation
MBD–Fc protein was produced as previously described [12]. For single-
gene analysis, typically 22.5 μg purified MBD–Fc protein per 40 μl Protein A–
Sepharose 4 Fast Flow beads (Amersham Biosciences, Piscataway, NJ, USA)
for a single assay was rotated in 2 ml TBS overnight at 4°C. On the next day, the
MBD–Fc beads (40 μl/assay) were transferred and dispersed into 0.5-ml
Ultrafree-MC centrifugal filter devices (Millipore, Billerica, MA, USA) and
spin-washed twice with buffer A (20 mM Tris–HCl, pH 8.0, 2 mM MgCl2,
0.5 mM EDTA, 350 mM NaCl, 0.1% NP-40). Sonicated DNA (300 ng) was
added to the washed MBD–Fc beads in 350 μl buffer A and rotated for 3 h at
4°C. Beads were centrifuged to recover unbound DNA fragments (350 mM
fraction) and subsequently washed twice with 200 μl/150 μl of buffers
containing increasing NaCl concentrations (400, 500, 570, and 1000 mM). The
flowthrough of each washing step was collected in separate tubes and desalted
using a QIAquick PCR Purification Kit (Qiagen). In parallel, 300 ng sonicated
input DNA was resuspended in 350 μl buffer E (20 mM Tris–HCl, pH 8.0,
2 mMMgCl2, 0.5 mM EDTA, 1000 mM NaCl, 0.1% NP-40) and desalted using
a QIAquick PCR Purification Kit (Qiagen) as a control. This MCIp protocol was
scaled up to generate DNA fragments for direct microarray hybridization. Here,
for each sample, 84 μg purified MBD–Fc protein was added to 200 μl Protein
A–Sepharose beads (Amersham Biosciences) in 15 ml TBS and rotated
overnight at 4°C. For the precipitation, 2-ml Ultrafree-MC centrifugal filter
devices (Millipore) were used and 4 μg of sonicated DNA was added to the
washed MBD–Fc beads in 2000 μl buffer A. Unbound DNA fragments
(350 mM fraction) were collected and desalted using a QIAquick PCR
Purification Kit (Qiagen) before subsequent labeling.
Real-time genomic PCR
Primers were designed using PerlPrimer Software (http://perlprimer.
sourceforge.net) and controlled using PCR and BLAT functions of the UCSC
Genome Browser (http://genome.ucsc.edu/). Enrichment of a specific fragment
in the MCIp eluate was detected and quantified relative to the genomic input by
real-time PCR on a Mastercycler EP Realplex (Eppendorf, Hamburg, Germany)
using the QuantiTect SYBR Green PCR Kit (Qiagen) according to the
manufacturer’s instructions. Primer sequences are given in Supplementary Table
2. Cycling parameters were denaturation at 95°C for 15 min and amplification at
95°C for 12 s, 57°C for 20 s, 72°C for 25 s, for 50 cycles. The specificity of the
PCR was controlled by melting-curve analysis. The relative amounts of
322 E. Schilling, M. Rehli / Genomics 90 (2007) 314–323amplified fragment were calculated from a standard curve plotting four different
concentrations of log dilutions of the genomic input DNA against the PCR cycle
number at which the measured fluorescence intensity reached a fixed value. For
each gene analyzed, at least two independent MCIp preparations were measured
in duplicate. For the monocyte samples, two independent samples revealed the
same small degree of deviation as technical replicates from liver and brain and
were therefore analyzed in combination. Heat maps were created using Spotfire
Decision Site Software 7.0 (Spotfire, Göteborg, Sweden). The mean percentage
of totally amplified fragment (sum of all five MCIp fractions) in each individual
MCIp fraction is graphically displayed. Black represents 100%, white represents
0%, and intermediate values are displayed in gray.
Microarray handling and analysis
To generate fluorescently labeled DNA for microarray hybridization the
350 mM fraction of a MCIp immunoprecipitation from somatic and testis cells,
genomic DNAwas labeled directly with Alexa Fluor 555–aha–dCTP and Alexa
Fluor 647–aha–dCTP, respectively, using the BioPrime Plus Array CGH
Genomic Labeling System (Invitrogen, Carlsbad, CA, USA). The labeling
reaction was carried out according to the manufacturer’s manual. The differently
labeled genomic DNA fragments of two tissues were combined to a final volume
of 150 μl, supplemented with 50 μg Cot-1 DNA (Invitrogen), 50 μl of Agilent
blocking agent (10-fold) (Agilent Technologies, Böblingen, Germany), and
250 μl Agilent hybridization buffer (2-fold) as supplied in the Agilent oligo
aCGH Hybridization Kit. The sample was heated to 95°C for 3 min, mixed, and
subsequently incubated at 37°C for 30 min and spun down afterward for 1 min.
Hybridization on Human Proximal Promoter microarrays (Agilent) was then
carried out at 65°C for 40 h using an Agilent SureHyb chamber and an Agilent
hybridization oven. Slides were washed in Wash I (6× SSPE, 0.005% N-
lauroylsarcosine) at room temperature for 5 min and inWash II (0.06× SSPE) for
an additional 5 min. Afterward slides were dried and incubated using acetonitrile
and Agilent ozone protection solution, respectively, for 30 s. Images were
scanned immediately and analyzed using a DNA microarray scanner (Agilent).
Microarray images were processed using Feature Extraction Software 8.5
(Agilent) using the standard CGH protocol and a rank consistent list of
normalization genes. The latter contained all probes with a CpG index above 78
(more than 78 CpG residues in a region of 350 bp upstream and downstream of a
probe). Processed data were imported into Microsoft Office Excel 2003 for
further analysis. Graphical presentations of datasets were obtained using
Spotfire Decision Site Software 7.0 (Spotfire).
Statistical calculations
The statistical significance of log ratio values obtained for individual
microarray probes was calculated using the “most conservative error model”
function of Feature Extraction Software 8.5 (Agilent), by which both a
propagated and a Universal error model are evaluated and the higher p value
(more conservative estimate of error) is reported. Error models are described in
detail in the Feature Extraction Software manual (Agilent). For the analysis of
concordance or differences of proportions of categorical values, numbers were
tabulated in contingency tables and analyzed by the χ2 test using the GraphPad
Prism software (GraphPad Software, San Diego, CA, USA).
Databases for sequence analysis
The relative locations of microarray probe, CpG islands, and Alu repeats
were determined using the UCSC Genome Browser (http://genome.ucsc.edu/).
Tissue expression profiles were obtained from the two reference databases for
gene expression, GNF SymAtlas (http://symatlas.gnf.org/SymAtlas/) and
RefEXA (http://www.lsbm.org/site_e/database/).
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